WHO ICTRP trial
Efficacy and safety of XM22 in patients with non small cell lung cancer…
EUCTR2009-016000-22-BG · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-016000-22-BG |
|---|---|
| Public title | Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study |
| Scientific title | Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study |
| Primary sponsor | BioGeneriX AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Bulgaria |
| Conditions | Non Small Cell Lung Cancer MedDRA version: 12.0 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIB MedDRA version: 12.0 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV |
| Interventions | Product Code: XM22 Pharmaceutical Form: Solution for injection CAS Number: 1117844-87-7 Current Sponsor code: XM22 Other descriptive name: GlycoPEGylated r-metHuG-CSF Concentration unit: mg/ml milligram(s)/millilitre Concentration type… |
| Registration date | Jan 29, 2010 |
| Target size | 485 |
| Secondary IDs | XM22-04 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: